1887

Journal of General Virology header logo

Volume 89, Issue 11

Epstein–Barr virus nuclear antigen-1 renders lymphocytes responsive to IL-2 but not IL-15 for survival Free

Abstract

Epstein–Barr virus nuclear antigen-1 (EBNA-1) is the only latent protein expressed in all virus-associated tumours. It plays a critical role in viral propagation and in the replication, episomal maintenance and partitioning of the viral genome. However, its tumorigenic potential is debated. We have previously shown that lymphocytes from a tumour-prone, EBNA-1-expressing, transgenic mouse line show increased responsiveness to interleukin-2 (IL-2). It was important to determine whether this property was unique to the transgenic line or whether it is a general consequence of EBNA-1 expression in B cells. In order to distinguish between these possibilities, explanted lymphocytes from two independent transgenic mouse lines were examined. The lymphocytes from both lines showed enhanced proliferation rates compared with controls. The transgenic lymphocytes survived for extended periods in culture, dependent on the dose of IL-2, while IL-15 (the receptor of which shares the and chain components of the IL-2 receptor) induced little effect. In accordance with this, transgenic B cells showed enhanced induction of expression of the IL-2 receptor chain (CD25), which modulates affinity for the ligand. As this phenotype is evident in lymphocytes from mice of both lines, it is necessarily independent of any transgene insertion site effects and may be attributed to EBNA-1 expression. Furthermore, 10/12 tumour-bearing transgenic mice had elevated IL-2 levels in serum and 4/6 tumours were CD25 positive. IL-2 is normally produced by activated T cells ; thus, chronic immune activation or modulation could elicit this unique mode of virus-infected cell survival.

  • Received:
  • Accepted:
  • Published Online:
SGM
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.83296-0
2008-11-01
2024-04-25
Loading full text...

Full text loading...

/deliver/fulltext/jgv/89/11/2821.html?itemId=/content/journal/jgv/10.1099/vir.0.83296-0&mimeType=html&fmt=ahah

References

  1. Adams J. M., Harris A. W., Pinkert C. A., Corcoran L. M., Alexander W. S., Cory S., Palmiter R. D., Brinster R. L. 1985; The c- myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318:533–538 [CrossRef]
     [Google Scholar]
  2. Caldwell R. G., Wilson J. B., Anderson S. J., Longnecker R. 1998; Epstein–Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9:405–411 [CrossRef]
     [Google Scholar]
  3. Caldwell R. G., Brown R. C., Longnecker R. 2000; Epstein–Barr virus LMP2A-induced B-cell survival in two unique classes of  μLMP2A transgenic mice. J Virol 74:1101–1113 [CrossRef]
     [Google Scholar]
  4. Ceccarelli D. F., Frappier L. 2000; Functional analyses of the EBNA1 origin DNA binding protein of Epstein–Barr virus. J Virol 74:4939–4948 [CrossRef]
     [Google Scholar]
  5. Chittenden T., Lupton S., Levine A. J. 1989; Functional limits of oriP , the Epstein–Barr virus plasmid origin of replication. J Virol 63:3016–3025
     [Google Scholar]
  6. Cipres A., Gala S., Martinez A. C., Merida I., Williamson P. 1999; An IL-2 receptor β subdomain that controls Bcl-XL expression and cell survival. Eur J Immunol 29:1158–1167 [CrossRef]
     [Google Scholar]
  7. Drotar M. E., Silva S., Barone E., Campbell D., Tsimbouri P., Jurvansu J., Bhatia P., Klein G., Wilson J. B. 2003; Epstein–Barr virus nuclear antigen-1 and Myc cooperate in lymphomagenesis. Int J Cancer 106:388–395 [CrossRef]
     [Google Scholar]
  8. Gaffen S. L. 2001; Signaling domains of the interleukin 2 receptor. Cytokine 14:63–77 [CrossRef]
     [Google Scholar]
  9. Gahn T. A., Sugden B. 1995; An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein–Barr virus LMP gene. J Virol 69:2633–2636
     [Google Scholar]
  10. Grasser F. A., Murray P. G., Kremmer E., Klein K., Remberger K., Feiden W., Reynolds G., Niedobitek G., Young L. S., Mueller-Lantzsch N. 1994; Monoclonal antibodies directed against the Epstein–Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease. Blood 84:3792–3798
     [Google Scholar]
  11. Holowaty M. N., Zeghouf M., Wu H., Tellam J., Athanasopoulos V., Greenblatt J., Frappier L. 2003; Protein profiling with Epstein–Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP/USP7. J Biol Chem 278:29987–29994 [CrossRef]
     [Google Scholar]
  12. Humme S., Reisbach G., Feederle R., Delecluse H. J., Bousset K., Hammerschmidt W., Schepers A. 2003; The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc Natl Acad Sci U S A 100:10989–10994 [CrossRef]
     [Google Scholar]
  13. Johnson-Leger C., Christenson J. R., Holman M., Klaus G. G. 1998; Evidence for a critical role for IL-2 in CD40-mediated activation of naive B cells by primary CD4 T cells. J Immunol 161:4618–4626
     [Google Scholar]
  14. Kang M. S., Lu H., Yasui T., Sharpe A., Warren H., Cahir-McFarland E., Bronson R., Hung S. C., Kieff E. 2005; Epstein–Barr virus nuclear antigen 1 does not induce lymphoma in transgenic FVB mice. Proc Natl Acad Sci U S A 102:820–825 [CrossRef]
     [Google Scholar]
  15. Kapoor P., Frappier L. 2003; EBNA1 partitions Epstein–Barr virus plasmids in yeast cells by attaching to human EBNA1-binding protein 2 on mitotic chromosomes. J Virol 77:6946–6956 [CrossRef]
     [Google Scholar]
  16. Kawa K. 2000; Epstein–Barr virus-associated diseases in humans. Int J Hematol 71:108–117
     [Google Scholar]
  17. Kennedy G., Komano J., Sugden B. 2003; Epstein–Barr virus provides a survival factor to Burkitt's lymphomas. Proc Natl Acad Sci U S A 100:14269–14274 [CrossRef]
     [Google Scholar]
  18. Kube D., Vockerodt M., Weber O., Hell K., Wolf J., Haier B., Grasser F. A., Muller-Lantzsch N., Kieff E. other authors 1999; Expression of Epstein–Barr virus nuclear antigen 1 is associated with enhanced expression of CD25 in the Hodgkin cell line L428. J Virol 73:1630–1636
     [Google Scholar]
  19. Lam N., Sugden B. 2003; CD40 and its viral mimic, LMP1: similar means to different ends. Cell Signal 15:9–16 [CrossRef]
     [Google Scholar]
  20. Lee M. A., Diamond M. E., Yates J. L. 1999; Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein–Barr virus. J Virol 73:2974–2982
     [Google Scholar]
  21. Li M., Brooks C. L., Kon N., Gu W. 2004; A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 13:879–886 [CrossRef]
     [Google Scholar]
  22. Lord J. D., McIntosh B. C., Greenberg P. D., Nelson B. H. 2000; The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc , bcl-2 , and bcl-x genes through the trans -activation domain of Stat5. J Immunol 164:2533–2541 [CrossRef]
     [Google Scholar]
  23. Miller C. L., Burkhardt A. L., Lee J. H., Stealey B., Longnecker R., Bolen J. B., Kieff E. 1995; Integral membrane protein 2 of Epstein–Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 2:155–166 [CrossRef]
     [Google Scholar]
  24. Moreau J. L., Chastagner P., Tanaka T., Miyasaka M., Kondo M., Sugamura K., Theze J. 1995; Control of the IL-2 responsiveness of B lymphocytes by IL-2 and IL-4. J Immunol 155:3401–3408
     [Google Scholar]
  25. Nakagawa T., Hirano T., Nakagawa N., Yoshizaki K., Kishimoto T. 1985; Effect of recombinant IL-2 and gamma-IFN on proliferation and differentiation of human B cells. J Immunol 134:959–966
     [Google Scholar]
  26. Sadlack B., Merz H., Schorle H., Schimpl A., Feller A. C., Horak I. 1993; Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75:253–261 [CrossRef]
     [Google Scholar]
  27. Saridakis V., Sheng Y., Sarkari F., Holowaty M. N., Shire K., Nguyen T., Zhang R. G., Liao J., Lee W. other authors 2005; Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein–Barr nuclear antigen 1 implications for EBV-mediated immortalization. Mol Cell 18:25–36 [CrossRef]
     [Google Scholar]
  28. Tsimbouri P., O'Donnell M. A., Wilson J. B. 2001; Selection and enrichment of B-cells from lymphoid tissues. Methods Mol Biol 174:411–421
     [Google Scholar]
  29. Tsimbouri P., Drotar M. E., Coy J. L., Wilson J. B. 2002; bcl-xL and RAG genes are induced and the response to IL-2 enhanced in  μEBNA-1 transgenic mouse lymphocytes. Oncogene 21:5182–5187 [CrossRef]
     [Google Scholar]
  30. Willerford D. M., Chen J., Ferry J. A., Davidson L., Ma A., Alt F. W. 1995; Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3:521–530 [CrossRef]
     [Google Scholar]
  31. Wilson J. B., Drotar M. E. 2001; Considerations in generating transgenic mice: DNA, RNA and protein extractions from tissues–rapid and effective blotting. Methods Mol Biol 174:361–377
     [Google Scholar]
  32. Wilson J. B., Levine A. J. 1992; The oncogenic potential of Epstein–Barr virus nuclear antigen 1 in transgenic mice. Curr Top Microbiol Immunol 182:375–384
     [Google Scholar]
  33. Wilson J. B., Bell J. L., Levine A. J. 1996; Expression of Epstein–Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J 15:3117–3126
     [Google Scholar]
  34. Zetterberg H., Borestrom C., Nilsson T., Rymo L. 2004; Multiple EBNA1-binding sites within oriPI are required for EBNA1-dependent transactivation of the Epstein–Barr virus C promoter. Int J Oncol 25:693–696
     [Google Scholar]
  35. Zubler R. H., Lowenthal J. W., Erard F., Hashimoto N., Devos R., MacDonald H. R. 1984; Activated B cells express receptors for, and proliferate in response to, pure interleukin 2. J Exp Med 160:1170–1183 [CrossRef]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.83296-0
Loading
Epstein–Barr virus nuclear antigen-1 renders lymphocytes responsive to IL-2 but not IL-15 for survival
J. Gen. Virol. 89, 2821 (2008); https://doi.org/10.1099/vir.0.83296-0
/content/journal/jgv/10.1099/vir.0.83296-0
/content/journal/jgv/10.1099/vir.0.83296-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error